Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 2046Triple Negative Breast Neoplasms 208Neoplasm Metastasis 133Neoplasms 119Carcinoma, Non-Small-Cell Lung 96Breast Neoplasms, Male 95Ovarian Neoplasms 89Colorectal Neoplasms 70Lung Neoplasms 67Carcinoma, Intraductal, Noninfiltrating 63Melanoma 57Prostatic Neoplasms 55Pancreatic Neoplasms 47Breast Carcinoma In Situ 42Stomach Neoplasms 38Colonic Neoplasms 37Brain Neoplasms 36Carcinoma, Renal Cell 35Inflammatory Breast Neoplasms 33Head and Neck Neoplasms 32Urinary Bladder Neoplasms 29Pain 29Small Cell Lung Carcinoma 27Squamous Cell Carcinoma of Head and Neck 26Endometrial Neoplasms 25Sarcoma 23Fatigue 23Uterine Cervical Neoplasms 21Esophageal Neoplasms 21Multiple Myeloma 18

Interventions

pertuzumab 1atezolizumab 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × HER2-positive Metastatic Breast Cancer × Breast × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡